Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (13941)	7/3/2000 9:15:09 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

"By October 1999 and a short three years after launch, ALPHAGAN, Allergans premier glaucoma therapy, was the first eye prescription product in Allergans history to exceed sales of $100 million in the United States." Page 12 1999 annual report. Yes glaucoma is a bigger market and accounts for about 40% of the sales of opthalmic drugs, in the U.S. It is not an anti infective. My point remains that far from saying that this area will provide a sales bonanza of billions of dollars of sales, I have said the market for each one of whatever product is developed will be modest and it will take three years, ( I now add at least), to get to this modest $100 million figure. O.K. that's my point. What is your point? Get the AGN annual report. Ocuflox and Acular are its' antiinfective products